Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT ID: NCT05476770
Last Updated: 2024-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
54 participants
INTERVENTIONAL
2022-11-11
2027-11-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells.
The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date.
This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy.
The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.
About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1
Tagraxofusp
-Days 1-5
IT Therapy (may include methotrexate, cytarabine, or triple IT)
* Day 1
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
Tagraxofusp
Dose will be assigned at study entry. Give IV over 15 minutes.
Methotrexate
Give intrathecally:
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients ≥9 years of age
Cytarabine IT
Give intrathecally:
* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients ≥3 years of age
If given as part of Triple IT Therapy:
AML Patients:
Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Hydrocortisone
Given intrathecally.
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg
AML Patients:
Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Part 2 - Cohort A
Tagraxofsup
-Days 4-8
Fludarabine -Days 1-5
Cytarabine
-Days 1-5
IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy
* Day 1
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
CNS2/3 IT Therapy
* Days 1, 8, 15, and 22
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
Tagraxofusp
Dose will be assigned at study entry. Give IV over 15 minutes.
Fludarabine
30 mg/m\^2 will be given IV over 30 minutes on days 1-5.
Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.
Cytarabine
2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
Methotrexate
Give intrathecally:
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients ≥9 years of age
Cytarabine IT
Give intrathecally:
* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients ≥3 years of age
If given as part of Triple IT Therapy:
AML Patients:
Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Hydrocortisone
Given intrathecally.
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg
AML Patients:
Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Part 2 - Cohort B
Tagraxofsup
-Days 8-12
Dexamethasone -Days 1-5
Vincristine
-Days 1, 8, 15, and 22
IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy
* Day 1
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
CNS2/3 IT Therapy
* Days 1, 8, 15, and 22
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
Tagraxofusp
Dose will be assigned at study entry. Give IV over 15 minutes.
Dexamethasone
* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.
* Any oral formulation of dexamethasone is acceptable.
* IV may be given if oral formulation is not tolerated
Vincristine
* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.
* Infusion will start 30 minutes after start of tagraxofusp on day 8.
Methotrexate
Give intrathecally:
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients ≥9 years of age
Cytarabine IT
Give intrathecally:
* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients ≥3 years of age
If given as part of Triple IT Therapy:
AML Patients:
Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Hydrocortisone
Given intrathecally.
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg
AML Patients:
Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Part 2 - Cohort C
Tagraxofsup -Days 1-5
Azacitidine
-Days 1-5
IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy
* Day 1
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
CNS2/3 IT Therapy
* Days 1, 8, 15, and 22
* Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator
Tagraxofusp
Dose will be assigned at study entry. Give IV over 15 minutes.
Azacitidine
* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.
* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.
Methotrexate
Give intrathecally:
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients ≥9 years of age
Cytarabine IT
Give intrathecally:
* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients ≥3 years of age
If given as part of Triple IT Therapy:
AML Patients:
Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Hydrocortisone
Given intrathecally.
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg
AML Patients:
Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tagraxofusp
Dose will be assigned at study entry. Give IV over 15 minutes.
Fludarabine
30 mg/m\^2 will be given IV over 30 minutes on days 1-5.
Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.
Cytarabine
2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
Dexamethasone
* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.
* Any oral formulation of dexamethasone is acceptable.
* IV may be given if oral formulation is not tolerated
Vincristine
* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.
* Infusion will start 30 minutes after start of tagraxofusp on day 8.
Azacitidine
* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.
* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.
Methotrexate
Give intrathecally:
* 8 mg for patients age 1-1.99
* 10 mg for patients age 2-2.99
* 12 mg for patients 3-8.99 years of age
* 15 mg for patients ≥9 years of age
Cytarabine IT
Give intrathecally:
* 30 mg for patients age 1-1.99
* 50 mg for patients age 2-2.99
* 70 mg for patients ≥3 years of age
If given as part of Triple IT Therapy:
AML Patients:
Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Hydrocortisone
Given intrathecally.
AML Patients:
Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg
AML Patients:
Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must be ≥ 1 and ≤21 years of age at the time of study enrollment.
Diagnosis
* Relapsed and/or refractory hematologic malignancy (including, but not limited to, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, mixed phenotype acute leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, and non-Hodgkin lymphoma).
* Tumor cells must demonstrate surface expression of CD123 at the time of enrollment by flow cytometry or immunohistochemistry, as defined by the local institution.
Disease Status:
Monotherapy, Part 1
* Second or greater relapse; or
* Refractory after 2 or more chemotherapy cycles; or
* First relapse after primary chemotherapy-refractory disease; or
* BPDCN in first relapse or refractory after 1 or more chemotherapy cycles
Combination therapy, Part 2
* First or greater relapse; or
* Refractory after 2 or more chemotherapy cycles; or
* BPDCN in first relapse or refractory after 1 or more chemotherapy cycles
For relapsed/refractory leukemia, patients must have:
* \>5% blasts in the bone marrow aspirate or biopsy by morphology or flow cytometry
* Patients with 1% - 5% blasts are eligible for Part 2, Cohort C (only), if A single bone marrow sample with flow cytometry and at least one other test (e.g. karyotype, FISH, PCR, or NGS) shows ≥ 1% leukemic blasts and/or flow cytometry demonstrates a stable or rising level of disease on two serial bone marrows.
For relapsed/refractory non-Hodgkin or Hodgkin lymphoma, patients must have:
* Histologic verification of relapse
* Measurable disease documented by radiographic criteria or bone marrow
* Patients in Part 1 may have sites of non-CNS extramedullary disease, but no CNS disease. Patients in Part 2 may have CNS disease and/or other non-CNS extramedullary disease. No cranial irradiation is allowed during the protocol therapy.
* Patients with Down syndrome are eligible to participate in Part 1 only.
Performance Level
* Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients ≤ 16 years of age (See Appendix I for Performance Scales). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Prior Therapy
* Anti-GVHD or agents to prevent organ rejection post-transplant - Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. At least 4 weeks must have elapsed after the last dose of GVHD meds.
Infection Criteria - Patients are excluded if they have:
* Positive blood culture within 48 hours of study enrollment;
* Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability.
* A positive fungal culture within 30 days of study enrollment.
* Active fungal, viral, bacterial, or protozoal infection requiring IV treatment. Chronic prophylaxis therapy to prevent infections is allowed.
* Patients will be excluded if they have a known allergy to any of the drugs used in the study.
* Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.
* Patients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.
Exclusion Criteria
* Hydroxyurea: Hydroxyurea can be initiated and/or continued for up to 24 hours prior to the start of protocol therapy.
* "Maintenance-style" therapy: therapy including vincristine (dosed a maximum of one-time weekly), oral 6-mercaptopurine, oral methotrexate (dosed a maximum of one-time weekly), intrathecal therapy (dosed a maximum of one-time weekly) and/or dexamethasone (dosed at ≤3 mg/m2/dose twice daily) or prednisone (dosed at ≤20 mg/m2/dose twice daily) can be continued for up to 24 hours prior to entering the study.
* Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD) and are at least 100 days post-transplant at the time of enrollment.
* Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with granulocyte colony stimulating factor (GCSF) or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).
* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
* Monoclonal antibodies: Maximum of 3 half-lives of the antibody or 21 days (whichever is shorter) must have elapsed after the last dose of monoclonal antibody.
* Immunotherapy: At least 30 days from last infusion of chimeric antigen receptor T cell (CART) therapy or tumor vaccine.
* Radiation Therapy (XRT):
1. ≥ 84 days must have passed, from the end of therapy, if patient received prior total body irradiation (TBI).
2. ≥ 42 days must have passed, from the end of therapy, if patient received craniospinal irradiation (CSI).
3. ≥ 14 days must have passed after whole brain radiotherapy or stereotactic radiation therapy.
4. No washout period is required for:
i. Extramedullary site other than CNS that is a maximum 10 x 10 cm total radiation non-CNS field. If the field is \> 10 x 10 cm, a 14-day washout period is required. ii. Local ocular radiotherapy as long as subject has measurable/evaluable disease outside the radiation port.
* Patients that have received other non-tagraxofusp CD123 targeting agents are eligible. Patients that have previously received tagraxofusp are not eligible.
Organ Function Requirements
Adequate Bone Marrow Function Defined as:
* Patients should not be known to be refractory to red blood cell or platelet transfusions.
* Blood counts are not required to be normal prior to enrollment on trial. However, platelet count must be ≥20,000/mm3 to initiate therapy (may receive platelet transfusions).
Adequate Renal Function Defined as:
* Patient must have a calculated creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender in the chart below:
Maximum Serum Creatinine (mg/dL):
* 1 to \< 2 years old - Male: 0.6, Female: 0.6
* 2 to \< 6 years old - Male:0.8, Female: 0.8
* 6 to \< 10 years old - Male: 1, Female: 1
* 10 to \< 13 years old - Male: 1.2, Female: 1.2
* 13 to \< 16 years old - Male: 1.5, Female: 1.4
* ≥ 16 years old - Male: 1.7, Female: 1.4
The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.
Adequate Liver Function Defined as:
* Total bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x institutional upper limit of normal for age
* SGPT (ALT) and SGOT (AST) must be less than 3x institutional upper limit of normal.
* Serum albumin ≥3.2 g/dL (albumin infusion independent).
Adequate Cardiac Function Defined as:
* Shortening fraction of ≥27% by echocardiogram, or
* Ejection fraction of ≥ 50% by gated radionuclide study/echocardiogram.
Adequate Pulmonary Function Defined as:
* Pulse oximetry \> 94% on room air (\> 90% if at high altitude)
* No evidence of dyspnea at rest and no exercise intolerance.
Reproductive Function
* Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
* Female patients with infants must agree not to breastfeed their infants while on this study.
* Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 12 weeks after the last dose of tagraxofusp.
Disease Status:
* Patients with CNS disease are not eligible for Part 1.
* Patients with isolated CNS disease are not eligible for Part 1 or Part 2.
* Patients with isolated non-CNS disease are eligible for Part 1 and Part 2.
Concomitant Medications
* Corticosteroids - Patients receiving corticosteroids for disease control who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
* Investigational Drugs - Patients who are currently receiving another investigational drug are not eligible. The definition of "investigational" for use in this protocol means any drug that is not licensed by the FDA, Health Canada or the Therapeutic Goods Administration to be sold in the countries they govern. (United States, Canada and Australia)
1 Year
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Therapeutic Advances in Childhood Leukemia Consortium
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Lamble, MD
Role: STUDY_CHAIR
Seattle Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital Orange County
Orange, California, United States
UCSF School of Medicine
San Francisco, California, United States
Children's Hospital Colorado
Denver, Colorado, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Children's Healthcare of Atlanta, Emory University
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Riley Hospital for Children
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
National Cancer Institute, Pediatric Oncology Branch
Bethesda, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States
Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota, United States
Children's Hospital New York-Presbyterian
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Carolina-Levine Children's Hospital
Charlotte, North Carolina, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Rainbow Babies
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
University of Texas, Southwestern
Dallas, Texas, United States
Cook Children's Hospital
Fort Worth, Texas, United States
Texas Children's Hospital/Baylor College of Medicine
Houston, Texas, United States
Primary Children's Hospital
Salt Lake City, Utah, United States
Seattle Children's Hospital
Seattle, Washington, United States
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Sydney Children's Hospital
Sydney, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Julio Barredo, MD
Role: primary
Sandeep Batra, MD
Role: primary
Nathan Gossai, MD
Role: primary
Maria Sulis, MD, MS
Role: primary
Robin Norris, MD
Role: primary
Jeffrey Rubnitz, MD
Role: primary
Tamra Slone, MD
Role: primary
Eric Schafer, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T2020-006
Identifier Type: -
Identifier Source: org_study_id